Suppressive influences in the immune response to cancer
- PMID: 19307988
- DOI: 10.1097/CJI.0b013e3181837276
Suppressive influences in the immune response to cancer
Abstract
Although much evidence has been gathered demonstrating that immune effectors can play a significant role in controlling tumor growth under natural conditions or in response to therapeutic manipulation, it is clear that malignant cells do evade immune surveillance in most cases. Considering that anticancer active specific immunotherapy seems to have reached a plateau of results and that currently no vaccination regimen is indicated as a standard anticancer therapy, the dissection of the molecular events underlying tumor immune escape is the necessary condition to make anticancer vaccines a therapeutic weapon effective enough to be implemented in the routine clinical setting. Recent years have witnessed significant advances in our understanding of the molecular mechanisms underlying tumor immune escape. These mechanistic insights are fostering the development of rationally designed therapeutics aimed to revert the immunosuppressive circuits that undermine an effective antitumor immune response. In this review, the best characterized mechanisms that allow cancer cells to evade immune surveillance are overviewed and the most debated controversies constellating this complex field are highlighted.
Similar articles
-
Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.Med Res Rev. 2008 May;28(3):413-44. doi: 10.1002/med.20110. Med Res Rev. 2008. PMID: 17694549 Review.
-
Tumor-host immune interactions and dendritic cell dysfunction.Adv Cancer Res. 2004;92:13-27. doi: 10.1016/S0065-230X(04)92002-7. Adv Cancer Res. 2004. PMID: 15530555 Review.
-
[Immune response and cancer].Bull Cancer. 2008 Jan;95(1):57-67. doi: 10.1684/bdc.2008.0558. Bull Cancer. 2008. PMID: 18230571 Review. French.
-
Priming anticancer active specific immunotherapy with dendritic cells.Curr Opin Investig Drugs. 2005 Jun;6(6):576-81. Curr Opin Investig Drugs. 2005. PMID: 15988908 Review.
-
The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.Immunol Rev. 2008 Apr;222:277-86. doi: 10.1111/j.1600-065X.2008.00621.x. Immunol Rev. 2008. PMID: 18364008 Review.
Cited by
-
Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.Clin Exp Metastasis. 2014 Feb;31(2):185-98. doi: 10.1007/s10585-013-9619-0. Epub 2013 Oct 6. Clin Exp Metastasis. 2014. PMID: 24096737 Free PMC article.
-
Vaccine immunotherapy for prostate cancer: from mice to men.Immunol Res. 2014 Aug;59(1-3):229-35. doi: 10.1007/s12026-014-8531-2. Immunol Res. 2014. PMID: 24847764
-
Immune-suppressive properties of the tumor microenvironment.Cancer Immunol Immunother. 2013 Jul;62(7):1137-48. doi: 10.1007/s00262-013-1434-6. Epub 2013 May 11. Cancer Immunol Immunother. 2013. PMID: 23666510 Free PMC article. Review.
-
Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities.Curr Treat Options Oncol. 2023 Dec;24(12):1703-1719. doi: 10.1007/s11864-023-01143-7. Epub 2023 Nov 14. Curr Treat Options Oncol. 2023. PMID: 37962824 Review.
-
Myeloid - derived suppressor cells in Type 1 diabetes are an expanded population exhibiting diverse T-cell suppressor mechanisms.PLoS One. 2020 Nov 18;15(11):e0242092. doi: 10.1371/journal.pone.0242092. eCollection 2020. PLoS One. 2020. PMID: 33206686 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources